(2R,3R,4R,5R)-2-((isobutyryloxy)methyl)-5-(2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate)

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: (2R,3R,4R,5R)-2-((isobutyryloxy)methyl)-5-(2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate)
• 英文别名: 2',3',5'-tri0isobutyl-zebularine；[(2R,3R,4R,5R)-3,4-bis(2-methylpropanoyloxy)-5-(2-oxopyrimidin-1-yl)oxolan-2-yl]methyl 2-methylpropanoate
• 化学式: C₂₁H₃₀N₂O₈
• 分子量: 438.478
• InChiKey: XMYFEFBSYPLFHQ-QBPKDAKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  121
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  异丁酸酐 、 4-脱氧尿苷 在 4-二甲氨基吡啶 二氯甲烷 、 碳酸氢钠 、 magnesium sulfate 、 silica gel 、 正己烷 、 乙酸乙酯 作用下， 以 吡啶 为溶剂， 反应 15.0h， 以to give the compound 23 (1.0 g, 52%) as a white solid的产率得到(2R,3R,4R,5R)-2-((isobutyryloxy)methyl)-5-(2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate)
  参考文献：
  名称：

  MUTUAL PRODRUG COMPRISING SHORT CHAIN FATTY ACIDS AND ZEBULARINE OR 1'-CYANO-CYTARABINE FOR CANCER TREATMENT

  摘要：

  本发明提供了包含抗癌核苷和短链脂肪酸的相互前药；制备相互前药的方法；通过给予相互前药进行治疗的方法；以及包含相互前药的制药组合物。此外，本发明的相互前药可用作治疗癌症疾病和病状的治疗剂。

  公开号：

  US20160228562A1

文献信息

• [EN] MUTUAL PRODRUG COMPRISING SHORT CHAIN FATTY ACIDS AND ZEBULARINE OR 1'-CYANO-CYTARABINE FOR CANCER TREATMENT<br/>[FR] PROMÉDICAMENT RÉCIPROQUE COMPORTANT DES ACIDES GRAS À CHAÎNE COURTE ET DE LA ZÉBULARINE OU DE LA 1'-CYANO-CYTARABINE POUR UN TRAITEMENT DE CANCER
  申请人：KAINOS MEDICINE INC

  公开号：WO2015072784A1

  公开（公告）日：2015-05-21

  The present invention provides mutual prodrugs comprising anti-cancer nucleosides and short chain fatty acids; methods for production of the mutual prodrugs; methods of treatment comprising administration of the mutual prodrugs; and pharmaceutical compositions comprising the mutual prodrugs. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer diseases and conditions.

  本发明提供了包括抗癌核苷和短链脂肪酸的相互伴侣药物；相互伴侣药物的制备方法；包括给予相互伴侣药物的治疗方法；以及包括相互伴侣药物的药物组合物。此外，本发明的相互伴侣药物可用作治疗癌症疾病和症状的治疗剂。
• Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment
  申请人：KAINOS MEDICINE, INC.

  公开号：US10500224B2

  公开（公告）日：2019-12-10

  The present invention provides mutual prodrugs comprising anti-cancer nucleosides and short chain fatty acids; methods for production of the mutual prodrugs; methods of treatment comprising administration of the mutual prodrugs; and pharmaceutical compositions comprising the mutual prodrugs. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer diseases and conditions.

  本发明提供了包含抗癌核苷和短链脂肪酸的互为原药；互为原药的生产方法；包括服用互为原药的治疗方法；以及包含互为原药的药物组合物。此外，本发明的互为原药可用作治疗癌症疾病和病症的治疗剂。
• MUTUAL PRODRUG COMPRISING SHORT CHAIN FATTY ACIDS AND ZEBULARINE OR 1'-CYANO-CYTARABINE FOR CANCER TREATMENT
  申请人：KAINOS MEDICINE, INC.

  公开号：US20160228562A1

  公开（公告）日：2016-08-11

  The present invention provides mutual prodrugs comprising anti-cancer nucleosides and short chain fatty acids; methods for production of the mutual prodrugs; methods of treatment comprising administration of the mutual prodrugs; and pharmaceutical compositions comprising the mutual prodrugs. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer diseases and conditions.

  本发明提供了包含抗癌核苷和短链脂肪酸的相互前药；制备相互前药的方法；通过给予相互前药进行治疗的方法；以及包含相互前药的制药组合物。此外，本发明的相互前药可用作治疗癌症疾病和病状的治疗剂。